---
title: "Daiichi Sankyo Company, Limited (DSNKY.US)"
type: "Symbol"
locale: "en"
url: "https://longbridge.com/en/quote/DSNKY.US.md"
symbol: "DSNKY.US"
name: "Daiichi Sankyo Company, Limited"
industry: "Pharmaceuticals"
datetime: "2026-05-20T14:40:07.750Z"
locales:
  - [en](https://longbridge.com/en/quote/DSNKY.US.md)
  - [zh-CN](https://longbridge.com/zh-CN/quote/DSNKY.US.md)
  - [zh-HK](https://longbridge.com/zh-HK/quote/DSNKY.US.md)
---

# Daiichi Sankyo Company, Limited (DSNKY.US)

## Company Overview

Daiichi Sankyo Company, Limited manufactures and sells pharmaceutical products in Japan, North America, Europe, and internationally. The company offers Enhertu to treat patients with HER2 positive and low breast cancer, HER2 positive gastric or gastroesophageal junction adenocarcinoma, and HER2 positive solid tumors; Turalio, an oral small molecule that targets colony stimulating factor 1 receptor, KIT proto-oncogene receptor tyrosine kinase, and FMS-like tyrosine kinase 3 harboring an internal tandem duplication mutation; Vanflyta, a FLT3 inhibitor for the treatment of adult patients with acute myeloid leukemia; and Injectafer, a ferric carboxymaltose injection to treat iron deficiency. It also provides Liziana and Savaysa, direct factor Xa inhibitors; Minnebro, Olmetec, Olmetec Plus, Rezaltas, Sevikar, and Sevikar HCT antihypertensive agents; Nilemdo, an oral treatment which lowers cholesterol; Nustendi, a fixed-dose combination tablet of bempedoic acid and ezetimibe to reduce cholesterol; and Efient, an anti-platelet agent. In addition, the company offers Canalia and Tenelia for the treatment of type 2 diabetes mellitus; Emgalty and Reyvow to treat migraine attacks; Pralia for the treatment of osteoporosis/inhibitor of the progression of bone erosion associated with rheumatoid arthritis; Ranmark to treat bone complications caused by bone metastasis from tumors; Tarlige for treating neuropathic pain; Venofer for the treatment of iron deficiency anemia; and Vimpat, an anti-seizure medication.

| Item | Detail |
|------|--------|
| Industry | Pharmaceuticals |
| Exchange | US Market |
| Website | [www.daiichisankyo.com](https://www.daiichisankyo.com) |

## Key Drivers
> *AI-analyzed key factors driving this stock's performance*


## Longbridge Financial Score™: C
> *Longbridge Financial Score™ — Proprietary multi-factor rating model by Longbridge*
> Updated: 2026-05-20T04:30:13.000Z

**Overall: C (0.42)**

**Industry**: Pharmaceuticals

| Metric | Value |
|--------|-------|
| Industry Ranking | 49 / 189 |
| Industry Median | C |
| Industry Average | C |

- **Style**: Value - Stocks where the company's main business is in a mature stage.
- **Scale**: Large - The company has stable operations, allowing for dependable long-term returns.

**Multi Score**: C

#### Style Score Score: 

| Indicator | Value | Rating |
|-----------|-------|--------|
| Revenue YoY | 13.11% |  |
| Net Profit YoY | -11.69% |  |
| P/B Ratio | 2.88 |  |
| Dividend Ratio | 2.96% |  |

#### Size Score Score: 

| Indicator | Value | Rating |
|-----------|-------|--------|
| Market Cap | 30024278295.00 |  |
| Revenue | 13990324073.49 |  |

#### Multi Score Score: C

| Indicator | Value | Rating |
|-----------|-------|--------|
| ROE | 15.81% | A |
| Profit Margin | 12.24% | B |
| Gross Margin | 68.49% | A |
| Revenue YoY | 13.11% | B |
| Net Profit YoY | -11.69% | D |
| Total Assets YoY | 8.68% | B |
| Net Assets YoY | -3.87% | D |
| Cash Flow Margin | 29.88% | D |
| OCF YoY | 13.11% | B |
| Turnover | 0.57 | C |
| Gearing Ratio | 58.45% | D |

```chart-data:radar
{
  "title": "Longbridge Financial Score - Daiichi Sankyo Company, Limited",
  "chart_type": "radar",
  "dimensions": [
    {
      "name": "Style Score",
      "grade": "",
      "indicators": [
        {
          "name": "Revenue YoY",
          "value": "13.11%",
          "rating": ""
        },
        {
          "name": "Net Profit YoY",
          "value": "-11.69%",
          "rating": ""
        },
        {
          "name": "P/B Ratio",
          "value": "2.88",
          "rating": ""
        },
        {
          "name": "Dividend Ratio",
          "value": "2.96%",
          "rating": ""
        }
      ]
    },
    {
      "name": "Size Score",
      "grade": "",
      "indicators": [
        {
          "name": "Market Cap",
          "value": "30024278295.00",
          "rating": ""
        },
        {
          "name": "Revenue",
          "value": "13990324073.49",
          "rating": ""
        }
      ]
    },
    {
      "name": "Multi Score",
      "grade": "C",
      "indicators": [
        {
          "name": "ROE",
          "value": "15.81%",
          "rating": "A"
        },
        {
          "name": "Profit Margin",
          "value": "12.24%",
          "rating": "B"
        },
        {
          "name": "Gross Margin",
          "value": "68.49%",
          "rating": "A"
        },
        {
          "name": "Revenue YoY",
          "value": "13.11%",
          "rating": "B"
        },
        {
          "name": "Net Profit YoY",
          "value": "-11.69%",
          "rating": "D"
        },
        {
          "name": "Total Assets YoY",
          "value": "8.68%",
          "rating": "B"
        },
        {
          "name": "Net Assets YoY",
          "value": "-3.87%",
          "rating": "D"
        },
        {
          "name": "Cash Flow Margin",
          "value": "29.88%",
          "rating": "D"
        },
        {
          "name": "OCF YoY",
          "value": "13.11%",
          "rating": "B"
        },
        {
          "name": "Turnover",
          "value": "0.57",
          "rating": "C"
        },
        {
          "name": "Gearing Ratio",
          "value": "58.45%",
          "rating": "D"
        }
      ]
    }
  ]
}
```

## Valuation Analysis

| Metric | Current | Industry Ranking | High | Median | Low |
|--------|---------|-----------------|------|--------|-----|
| PE (TTM) | 17.53 | 31/189 | 23.53 | 21.95 | 17.06 |
| PB | 2.88 | 112/189 | 4.21 | 3.78 | 3.12 |
| PS (TTM) | 2.15 | 61/189 | 3.62 | 3.19 | 2.49 |
| Dividend Yield | 2.96% | 13/189 | 2.41% | 2.06% | 1.64% |

## Peer Comparison

| Rank | Name | Profit | Growth | Operation | Security | Cash | Rating |
| --- | --- | --- | --- | --- | --- | --- | --- |
| 01 | Cormedix (CRMD.US) | A | A | B | C | B | A |
| 02 | Eli Lilly (LLY.US) | A | A | B | D | B | B |
| 03 | ROCHE HOLDINGS AG (RHHVF.US) | A | B | B | D | B | B |
| 04 | Roche (RHHBY.US) | A | B | B | D | B | B |
| 05 | AstraZeneca (AZN.US) | A | B | C | D | B | B |

## Institutional View

### Analyst Rating Distribution

> As of 2026-05-11T04:00:00.000Z

Total Analysts: **2**

| Rating | Count | Percentage |
|--------|-------|-----------| 
| Buy | 2 | 100% |

### Target Price Forecast

| Metric | Price |
|--------|-------|
| Current Price | 16.43 |
| Highest Target | 29.00 |
| Lowest Target | 22.00 |

## References

- [Company Overview — Profile, executives, shareholders, business breakdown](https://longbridge.com/en/quote/DSNKY.US/overview.md)
- [Financial Reports — Income, balance sheet, cash flow, dividends](https://longbridge.com/en/quote/DSNKY.US/norm.md)
- [Related News](https://longbridge.com/en/quote/DSNKY.US/news.md)

---

> **Disclaimer: This article is for reference only and does not constitute any investment advice.**